<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008186</url>
  </required_header>
  <id_info>
    <org_study_id>408-C-1806</org_study_id>
    <nct_id>NCT04008186</nct_id>
  </id_info>
  <brief_title>A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone</brief_title>
  <official_title>A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study With Omaveloxolone in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the potential for clinical drug-drug interactions between
      omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug
      transporters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Actual">August 28, 2019</completion_date>
  <primary_completion_date type="Actual">August 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 - Maximum concentration (Cmax) of probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for midazolam, repaglinide, metformin, rosuvastatin, and digoxin to determine maximum observed concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 - Area under the plasma concentration-time curve of (AUC) for probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for midazolam, repaglinide, metformin, rosuvastatin, and digoxin to determine area under the curve (AUC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - Maximum concentration (Cmax) of omaveloxolone</measure>
    <time_frame>23 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - Area under the omaveloxolone concentration-time curve (AUC)</measure>
    <time_frame>23 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Maximum concentration (Cmax) of omaveloxolone</measure>
    <time_frame>23 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 - Area under the omaveloxolone concentration-time curve (AUC)</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 4 - Maximum concentration (Cmax) of omaveloxolone</measure>
    <time_frame>23 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 4 - Area under the omaveloxolone concentration-time curve (AUC)</measure>
    <time_frame>28 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>Omaveloxolone and Multiple Drugs (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively. Oral doses of 150 mg omaveloxolone on Days 12 to 27</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone &amp; Gemfibrozil (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone and Itraconazole (Part 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 200 mg itraconazole on Days 10 to 18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone and Verapamil (Part 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral doses of 150 mg omaveloxolone on Days 1 and 13. Oral doses of 120 mg verapamil on Days 10 to 18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone</intervention_name>
    <description>50 mg capsules</description>
    <arm_group_label>Omaveloxolone &amp; Gemfibrozil (Part 2)</arm_group_label>
    <arm_group_label>Omaveloxolone and Itraconazole (Part 3)</arm_group_label>
    <arm_group_label>Omaveloxolone and Multiple Drugs (Part 1)</arm_group_label>
    <arm_group_label>Omaveloxolone and Verapamil (Part 4)</arm_group_label>
    <other_name>RTA 408</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam oral solution</intervention_name>
    <description>2 mg/mL oral solution</description>
    <arm_group_label>Omaveloxolone and Multiple Drugs (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide 1 MG</intervention_name>
    <description>1 mg tablet</description>
    <arm_group_label>Omaveloxolone and Multiple Drugs (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MetFORMIN 500 Mg Oral Tablet</intervention_name>
    <description>500 mg tablet</description>
    <arm_group_label>Omaveloxolone and Multiple Drugs (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10 mg tablet</description>
    <arm_group_label>Omaveloxolone and Multiple Drugs (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin tablet</intervention_name>
    <description>0.25 mg tablet</description>
    <arm_group_label>Omaveloxolone and Multiple Drugs (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil Tablets</intervention_name>
    <description>600 mg tablet</description>
    <arm_group_label>Omaveloxolone &amp; Gemfibrozil (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole capsule</intervention_name>
    <description>100 mg capsule</description>
    <arm_group_label>Omaveloxolone and Itraconazole (Part 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil Pill</intervention_name>
    <description>120 mg tablet</description>
    <arm_group_label>Omaveloxolone and Verapamil (Part 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must satisfy all of the following criteria at the Screening Visit unless otherwise
        stated:

          -  Males or females, of any race, between 18 and 55 years of age, inclusive.

          -  Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a total body weight &gt;50
             kg.

          -  In good health.

          -  Females will not be pregnant or lactating, and females of childbearing potential and
             males will agree to use contraception.

          -  Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

        Exclusion Criteria:

        Subjects will be excluded from the study if they satisfy any of the following criteria at
        the Screening visit, unless otherwise stated:

          -  Significant history or clinical manifestation of any major system disorder, as
             determined by the investigator (or designee).

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance, unless approved by the investigator (or designee).

          -  History of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs (cholecystectomy will not be
             allowed; uncomplicated appendectomy and hernia repair will be allowed).

          -  History of alcoholism or drug/chemical abuse within 2 years prior to Check in (Day 1).

          -  Abnormal laboratory values considered clinically significant by the investigator

          -  Clinically significant abnormal 12 lead ECGs

          -  Personal history of unexplained syncopal events, or family history of long QT syndrome
             or sudden unexplained death in a young person.

          -  Pulse rate &lt;50 bpm or systolic blood pressure &lt;110 mmHg.

          -  Alcohol consumption of &gt;21 units per week for males and &gt;14 units for females.

          -  Positive urine drug screen or positive alcohol breath test result or positive urine
             drug screen.

          -  Positive hepatitis panel and/or positive human immunodeficiency virus test.
             Participation in a clinical study involving administration of an investigational drug
             (new chemical entity) in the past 30 days prior to dosing or 5 half lives (if known),
             whichever is longer, prior to dosing.

          -  Use or intend to use any medications/products known to alter drug absorption,
             metabolism, or elimination processes, including St. John's wort, within 30 days prior
             to dosing, unless deemed acceptable by the investigator (or designee).

          -  Have previously completed or withdrawn from this study or any other study
             investigating omaveloxolone, and have previously received the investigational product.

          -  Subjects who, in the opinion of the investigator (or designee), should not participate
             in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Zon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CRU) Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>RTA 408 capsules</keyword>
  <keyword>omaveloxolone</keyword>
  <keyword>omaveloxolone capsules</keyword>
  <keyword>DDI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

